Charles Lyon Quoted on Gene Patentability in BioPharm Insight

BioPharm Insight

 | April 2, 2012

 | Charles Lyon

Charles Lyon was quoted in “Myriad Gene Patent Case May Still Ultimately End up at Supreme Court, Despite Remand to Federal Circuit Following Prometheus Decision, Attorneys Say” in BioPharm Insight, an industry news and data resource for subscribers in the global biopharmaceutical community.  Mr. Lyon discusses why Myriad's claims may not be upheld in a closely watched case concerning patentability of inventions involving natural phenomena.  


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.